S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is carbon capture and why does it keep coming up at COP28?
Dozens of animals taken from Virginia roadside zoo as part of investigation
All the trading advice you’ve ever received boils down to this (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
All the trading advice you’ve ever received boils down to this (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is carbon capture and why does it keep coming up at COP28?
Dozens of animals taken from Virginia roadside zoo as part of investigation
All the trading advice you’ve ever received boils down to this (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
All the trading advice you’ve ever received boils down to this (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is carbon capture and why does it keep coming up at COP28?
Dozens of animals taken from Virginia roadside zoo as part of investigation
All the trading advice you’ve ever received boils down to this (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
All the trading advice you’ve ever received boils down to this (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is carbon capture and why does it keep coming up at COP28?
Dozens of animals taken from Virginia roadside zoo as part of investigation
All the trading advice you’ve ever received boils down to this (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
All the trading advice you’ve ever received boils down to this (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths

ProMIS Neurosciences Stock Price, News & Analysis (NASDAQ:PMN)

$1.15
-0.01 (-0.86%)
(As of 12/8/2023 ET)
Compare
Today's Range
$1.15
▼
$1.19
50-Day Range
$1.15
▼
$2.00
52-Week Range
$1.06
▼
$8.95
Volume
3,572 shs
Average Volume
13,986 shs
Market Capitalization
$21.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media

ProMIS Neurosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
595.7% Upside
$8.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.36) to ($1.08) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.57 out of 5 stars

Medical Sector

831st out of 932 stocks

Pharmaceutical Preparations Industry

389th out of 431 stocks

See Top Rated MarketRank™ Stocks Here

PMN stock logo

About ProMIS Neurosciences Stock (NASDAQ:PMN)

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

PMN Stock Price History

PMN Stock News Headlines

December 8, 2023 | americanbankingnews.com
ProMIS Neurosciences (NASDAQ:PMN) Trading Up 0.7%
November 14, 2023 | msn.com
ProMIS Neurosciences GAAP EPS of -$0.19 beats by $0.14
December 9, 2023 | DTI Trader (Ad)
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
September 6, 2023 | finance.yahoo.com
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 22, 2023 | msn.com
ProMIS Neurosciences scales 31% on $20.4M private placement
August 21, 2023 | finance.yahoo.com
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
May 15, 2023 | finance.yahoo.com
ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights
May 6, 2023 | theglobeandmail.com
Closing Bell: Promis Neurosciences Inc down on Friday (PMN)
December 9, 2023 | Autonomix (Ad)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
April 27, 2023 | theglobeandmail.com
Closing Bell: Promis Neurosciences Inc up on Thursday (PMN)
April 25, 2023 | finance.yahoo.com
Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Disease
April 24, 2023 | finance.yahoo.com
ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting
April 19, 2023 | theglobeandmail.com
Closing Bell: Promis Neurosciences Inc up on Tuesday (PMN)
April 18, 2023 | theglobeandmail.com
Closing Bell: Promis Neurosciences Inc down on Monday (PMN)
April 15, 2023 | theglobeandmail.com
Closing Bell: Promis Neurosciences Inc up on Friday (PMN)
April 10, 2023 | proactiveinvestors.com
ProMIS Neurosciences submits IND application for Alzheimer's treatment
See More Headlines
Receive PMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProMIS Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/13/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PMN
CUSIP
N/A
CIK
1374339
Web
www.promisneurosciences.com
Phone
(416) 847-6898
Fax
N/A
Employees
6
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$8.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+595.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.94)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-18,060,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-219.98%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.81
Quick Ratio
1.81

Sales & Book Value

Annual Sales
$10,000.00
Price / Sales
2,172.35
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.16) per share
Price / Book
-7.19

Miscellaneous

Outstanding Shares
18,890,000
Free Float
16,940,000
Market Cap
$21.72 million
Optionable
Not Optionable
Beta
0.53
The 10 Best AI Stocks to Own in 2024 Cover
The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Eugene Williams (Age 64)
    Co-Founder & Chairman
    Comp: $439.21k
  • Dr. Gail M. Farfel Ph.D. (Age 59)
    CEO & Director
    Comp: $177.23k
  • Dr. Neil R. Cashman M.D. (Age 71)
    Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director
    Comp: $333.8k
  • Mr. Gavin T. Malenfant (Age 59)
    Chief Operating Officer
    Comp: $413.49k
  • Mr. Daniel E. Geffken M.B.A. (Age 66)
    Chief Financial Officer
    Comp: $90.57k
  • Dr. Johanne Kaplan Ph.D. (Age 63)
    Chief Development Officer
    Comp: $264.77k
  • Dr. Ernest D. Bush Ph.D.
    Head of Pharmacology/Toxicology & Senior Consultant
  • Dr. David Wishart Ph.D.
    Chief Physics Officer
  • Mr. Dennis Chen Ph.D.
    Head of Manufacturing & Senior Consultant
  • Dr. Larry Douglas Altstiel M.D. (Age 73)
    Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions














PMN Stock Analysis - Frequently Asked Questions

Should I buy or sell ProMIS Neurosciences stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProMIS Neurosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PMN shares.
View PMN analyst ratings or view top-rated stocks.

What is ProMIS Neurosciences' stock price target for 2024?

2 brokerages have issued 12-month target prices for ProMIS Neurosciences' shares. Their PMN share price targets range from $8.00 to $8.00. On average, they anticipate the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 595.7% from the stock's current price.
View analysts price targets for PMN or view top-rated stocks among Wall Street analysts.

How have PMN shares performed in 2023?

ProMIS Neurosciences' stock was trading at $4.34 on January 1st, 2023. Since then, PMN shares have decreased by 73.5% and is now trading at $1.15.
View the best growth stocks for 2023 here.

When is ProMIS Neurosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024.
View our PMN earnings forecast.

How were ProMIS Neurosciences' earnings last quarter?

ProMIS Neurosciences, Inc. (NASDAQ:PMN) released its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.19) earnings per share for the quarter.

Who are ProMIS Neurosciences' major shareholders?

ProMIS Neurosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Affinity Asset Advisors LLC (3.10%).

How do I buy shares of ProMIS Neurosciences?

Shares of PMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PMN) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -